Differences in health related quality of life in the randomised ARTSCAN study; accelerated vs. conventional radiotherapy for head and neck cancer. A five year follow up
| Autor: | Britta Lödén, Eva Hammerlid, Per Fransson, Karin Söderström, Lars Franzén, Erik Lundin, Anders Ask, Eva Brun, Per Nilsson, Signe Friesland, Johanna Nyqvist, Elisabeth Kjellén, Helena Sjödin, Göran Laurell, Johan Reizenstein, Freddi Lewin, Gun Wickart-Johansson, Thomas Björk-Eriksson, Lars Ekberg, Jan Nyman, Björn Zackrisson |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Adult
Male Pediatrics medicine.medical_specialty 030218 nuclear medicine & medical imaging 03 medical and health sciences 0302 clinical medicine Conventional radiotherapy Quality of life medicine Humans Radiology Nuclear Medicine and imaging Prospective Studies Prospective cohort study Aged Health related quality of life Aged 80 and over business.industry Head and neck cancer Five year follow up Dose fractionation Hematology Middle Aged medicine.disease Oncology Head and Neck Neoplasms 030220 oncology & carcinogenesis Accelerated radiotherapy Physical therapy Carcinoma Squamous Cell Quality of Life Female Dose Fractionation Radiation business Follow-Up Studies |
| Zdroj: | Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 118(2) |
| ISSN: | 1879-0887 |
| Popis: | Health related quality of life (HRQoL) was assessed in the randomised, prospective ARTSCAN study comparing conventional radiotherapy (CF) with accelerated radiotherapy (AF) for head and neck cancer.750 patients with squamous cell carcinoma (of any grade and stage) in the oral cavity, oro-, or hypopharynx or larynx (except T1-2, N0 glottic carcinoma) without distant metastases were randomised to either conventional fractionation (2 Gy/day, 5 days/week in 49 days, total dose 68 Gy) or accelerated fractionation (1.1+2.0 Gy/day, 5 days/week in 35 days, total dose 68 Gy). HRQoL was assessed with EORTC QLQ-C30, QLQ-HN35 and HADS at baseline, at end of radiotherapy (eRT) and at 3 and 6 months and 1, 2 and 5 years after start of treatment.The AF group reported HRQoL was significantly lower at eRT and at 3 months for most symptoms, scales and functions. Few significant differences were noted between the groups at 6 months and 5 years. Scores related to functional oral intake never reached baseline.In comparison to CF, AF has a stronger adverse effect on HRQoL in the acute phase. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect